Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype
Clinical trial NCT01459913 · TERMINATED
Trial details
- NCT number
- NCT01459913
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2011-11-01
- Primary completion
- 2014-01-01
- Enrollment
- 239
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.